Reuters logo
BRIEF-Catabasis Pharmaceuticals reports positive DMD drug data
October 4, 2017 / 3:13 PM / 2 months ago

BRIEF-Catabasis Pharmaceuticals reports positive DMD drug data

Oct 4 (Reuters) - Catabasis Pharmaceuticals Inc:

* Catabasis Pharmaceuticals reports positive results from open-­label extension of phase 2 MoveDMD trial evaluating edasalonexent in duchenne muscular dystrophy

* Catabasis Pharmaceuticals says edasalonexent substantially slowed duchenne muscular dystrophy disease progression through 36 weeks in phase 2 trial

* Plans to initiate single global phase 3 trial with edasalonexent in patients with DMD regardless of mutation type in first half of 2018

* Catabasis Pharmaceuticals says top-­line results from single global phase 3 trial with edasalonexent expected in 2020

* Catabasis Pharmaceuticals says edasalonexent continued to be well tolerated with no safety signals observed to date in movedmd trial Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below